The GEO Group (GEO) – From Lease to Ownership


Wednesday, July 02, 2025

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 103 facilities totaling approximately 83,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Purchase. The GEO Group is purchasing the currently leased 770-bed Western Region Detention facility for $60 million, or $77,900/bed. GEO is currently leasing the facility at a cost of $5.1 million annually. GEO has had a long-term contract with the U.S. Marshals Service for use of the facility, which generates approximately $57 million of annualized revenue.

A Tax Savings. Expected to close by the end of July, the transaction is expected to be funded as a like kind real estate property exchange with proceeds from the previously announced sale of the GEO-owned  Lawton Correctional Facility, which is expected to close on July 25th, resulting in an estimated capital gains cash tax savings of approximately $9.5 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resources Connection (RGP) – A Cooperation Agreement and New Directors


Wednesday, July 02, 2025

Resources Connection, Inc. provides agile consulting services in North America, Europe, and the Asia Pacific. The company offers finance and accounting services, including process transformation and optimization, financial reporting and analysis, technical and operational accounting, merger and acquisition due diligence and integration, audit readiness, preparation and response, implementation of new accounting standards, and remediation support. It also provides information management services, such as program and project management, business and technology integration, data strategy, and business performance management. In addition, the company offers corporate advisory, strategic communications, and restructuring services; and corporate governance, risk, and compliance management services, such as contract and regulatory compliance, enterprise risk management, internal controls management, and operation and information technology (IT) audits. Further, it provides supply chain management services comprising strategy development, procurement and supplier management, logistics and materials management, supply chain planning and forecasting, and unique device identification compliance; and human capital services, including change management, organization development and effectiveness, compensation and incentive plan strategies, and optimization of human resources technology and operations. Additionally, the company offers legal and regulatory supporting services for commercial transactions, global compliance initiatives, law department operations, and law department business strategies and analytics. It also provides policyIQ, a proprietary cloud-based governance, risk, and compliance software application. The company was formerly known as RC Transaction Corp. and changed its name to Resources Connection, Inc. in August 2000. Resources Connection, Inc. was founded in 1996 and is headquartered in Irvine, California.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cooperation Agreement. Resources Connection has entered into a “Cooperation Agreement” with shareholder Circumference Group LLC. According to a Form 3 filing of June 30th, Circumference owns 1,289,243 RGP shares, representing 3.9% of the common shares outstanding as of March 31st.

Board Changes. As part of the Cooperation Agreement, RGP appointed Jeff Fox, founding partner and CEO of Circumference Group, and Filip Gyde, former CEO of Computer Task Group, to the Board. Current Board members Anthony Cherbak and Neil Dimick will retire from the Board following the conclusion of their terms in October 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

GoHealth (GOCO) – Credit Amendment Provides Reprieve


Wednesday, July 02, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Amended credit agreement. On June 30, the company announced an amendment to its credit agreement, extending the maturity of the company’s Class A Revolving Commitments from Q2 end to Q3 end. Moreover, any interest due on the revolver and refinanced term loans through that date will be paid in-kind. The amendment also waived financial covenant testing for Q2 and Q3, offering the company a temporary liquidity reprieve.

Cost of amendment. As part of the amendment, GoHealth will pay a 1.00% amendment fee to consenting lenders, which, along with all interest through September 30, will be paid in-kind and added to the principal balance of its loans. As a result, we estimate these provisions will increase the company’s outstanding debt by approximately $6 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – AZZ Acquires Canton Galvanizing, LLC


Wednesday, July 02, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Bolt-on acquisition. AZZ Inc. entered into an agreement to acquire all the assets of Canton Galvanizing, LLC, a privately held hot dip galvanizing company based in Canton, Ohio. While the terms of the transaction were not disclosed, AZZ expects the transaction to be accretive to earnings within the first year of operation. Founded in 2019, Canton provides hot-dip galvanizing to customers in the U.S. Midwest and specializes in coating small to mid-size parts.

Strengthens AZZ’s presence in the U.S. Midwest. The strategic acquisition expands AZZ’s Metal Coatings capabilities in the US. Midwest and increases its total galvanizing network to 42 sites in North America. It has been renamed AZZ Galvanizing – Canton East LLC. With a spinning operation and a 21-foot kettle, Canton is known for quick turnaround times and excellent customer service.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Russell Index Rebalancing Brings Fresh Opportunities to Small and Mid-Cap Investors

The annual Russell Index reconstitution, which took effect after market close on Friday, June 27, 2025, marked a significant milestone in the small and mid-cap investment landscape. This 37th annual reconstitution represents the final annual rebalancing before FTSE Russell transitions to a semi-annual schedule, making it particularly noteworthy for investors focused on emerging growth companies.

Historically, Russell Reconstitution Day represents the biggest trading close of the year, with last year’s event generating $220 billion in U.S. equity trading volume. This year’s rebalancing has brought several compelling additions to the Russell indexes, particularly in the biotechnology and technology sectors, offering new opportunities for investors seeking exposure to innovative small and mid-cap companies.

Notable New Additions to Watch

Among the most intriguing additions to the Russell indexes this year are several companies that exemplify the dynamic nature of today’s small-cap market. Tonix Pharmaceuticals (TNXP) announced its inclusion in both the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, representing a significant validation of the fully-integrated biotechnology company’s market position and growth trajectory.

Tonix’s addition is particularly noteworthy given the company’s focus on developing treatments across multiple therapeutic areas. The inclusion in these widely-followed indexes is expected to increase institutional investor attention and potentially improve liquidity for the stock, making it more accessible to a broader range of portfolio managers and ETF providers.

Eledon Pharmaceuticals (ELDN) represents another compelling story in the clinical-stage biopharmaceutical space. The company focuses on developing immune-modulating therapies for life-threatening conditions, positioning it at the forefront of innovative medical treatment development. With analyst price targets averaging $10.40 and ranging from $8.00 to $16.00, representing a potential 230% upside from recent trading levels, the stock demonstrates the significant growth potential that Russell Index inclusion can help unlock.

Comstock (LODE) and SKYX Platforms (SKYX) round out a diverse group of new additions that span multiple sectors, from natural resources to technology platforms. These companies represent the type of emerging businesses that the Russell reconstitution process is designed to capture, ensuring that the indexes remain representative of the evolving U.S. equity market landscape.

The Russell reconstitution process serves as a crucial barometer for middle market health and provides institutional validation for growing companies. The process realigns membership across the Russell 1000, Russell 2000, Russell 3000, and Russell Microcap indexes to reflect changes in market capitalization and structure, ensuring these benchmarks accurately represent the current market environment.

For investors focused on small and mid-cap opportunities, these new additions represent companies that have demonstrated sufficient growth, liquidity, and market acceptance to meet Russell’s stringent inclusion criteria. The reconstitution process, which began on April 30 and culminated with the June 27 implementation, involves comprehensive evaluation of company fundamentals and market positioning.

As the Russell indexes transition to semi-annual reconstitution in the future, this year’s additions take on added significance, representing the final cohort selected through the traditional annual process that has guided small-cap investing for decades.

To learn more about emerging opportunities in the small and mid-cap market, join us at Noble Capital Markets’ upcoming Virtual Equity Conference on October 8-9, where we’ll feature presentations from promising growth companies and insights from leading market experts.

Unicycive Therapeutics (UNCY) – CRL Letter Received As Second Manufacturer Generates Data


Tuesday, July 01, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Approval Delay Is Not A Surprise. Unicycive announced that it has received a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). This was expected following the announcement earlier this month stating that the FDA manufacturing inspection had found deficiencies with one of the OLC contract manufacturers. The company has switched to one of its other manufacturers, which we believe can resolve the issues quickly. We see approval possible around 4Q25 to 1Q26.

Plans To Address The Issues. Unicycive plans to hold a Type A meeting with the FDA to determine its requirements for resolution of the issues cited in the CRL. The company’s second manufacturer already produces OLC and has been generating data for FDA certification. This should allow Unicycive to submit any additional data requested quickly to resolve the issue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – Completes $575 Million Capital Raise


Tuesday, July 01, 2025

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Capital Raise. Kratos completed its previously announced offering of Kratos common stock, raising  $575 million in gross proceeds, at a public offering price of  $38.50 per share, for a total of 14,935,065 shares of common stock, which includes the exercise of the underwriter’s option to purchase additional shares. Net proceeds from the offering were approximately  $556 million. Noble Capital participated as a co-manager of the offering.

Use of Proceeds. Kratos expects to use the net proceeds of the offering to (i) fund investments and capital expenditures to scale and successfully execute on large, mission critical National Security priorities related to existing programs, recent program awards and significant high-probability pipeline opportunities; (ii) to finance important customer and program targeted acquisitions; (iii) and for general corporate purposes.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Great Lakes Dredge & Dock (GLDD) – Some Award Updates


Tuesday, July 01, 2025

Great Lakes Dredge & Dock Corporation is the largest provider of dredging services in the United States. In addition, Great Lakes is fully engaged in expanding its core business into the rapidly developing offshore wind energy industry. The Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprised of approximately 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Awards. Yesterday, Great Lakes provided an update on some recent awards. Each of the awards adds to the Company’s significant backlog, which stood at approximately $1 billion with an additional $265 million in low bids and options pending award at the end of the first quarter. The large backlog, with a majority being higher margin capital projects, provides strong visibility for 2025 and into 2026.

Woodside LNG. The Company received Notice to Proceed from Bechtel Energy for dredging work on the Woodside Louisiana LNG project. The first phase of work, which was awarded in the second quarter of 2025, includes the construction of a ship berthing basin for use by large LNG carriers, with potential for award of two options to expand the scope of construction for additional ship berths. Dredging operations are expected to commence in early 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Labor Market Shows Unexpected Strength as Job Openings Surge in May

The American labor market delivered a surprise in May, with job openings climbing to their highest point in over six months, according to fresh government data that has caught economists and Federal Reserve watchers off guard.

The Bureau of Labor Statistics reported Tuesday that available positions reached 7.76 million at the end of May, representing a substantial jump from April’s 7.39 million openings. This figure significantly exceeded analyst predictions, which had anticipated job openings would remain relatively flat at approximately 7.3 million positions.

The unexpected surge in available positions marks the strongest showing for job openings since November 2024, suggesting that despite broader economic uncertainties, employers continue to maintain robust demand for workers across various sectors.

While the job opening data painted an optimistic picture, other components of the Job Openings and Labor Turnover Survey revealed a more nuanced employment landscape. Hiring activity actually declined during the month, with companies bringing on 5.5 million new employees compared to 5.61 million in April. This translated to a hiring rate of 3.4%, down from the previous month’s 3.5%.

The data reveals what labor economists have characterized as a market in equilibrium, where demand for workers remains strong but actual hiring activity has moderated from the rapid pace seen in recent years. Both hiring and voluntary quit rates are currently operating near decade-low levels, indicating a more measured approach to job market transitions.

Interestingly, the quit rate—often viewed as a barometer of worker confidence—edged upward to 2.1% from April’s 2.0%. This modest increase suggests that while employees remain cautious about making career moves, some are beginning to show renewed confidence in finding alternative employment opportunities.

The labor market data arrives at a critical juncture for monetary policy discussions. Financial markets are closely monitoring employment trends as the Federal Reserve weighs potential interest rate adjustments in response to evolving economic conditions.

Current market expectations indicate approximately a 23% probability of a rate cut at the Fed’s July meeting, with odds rising to 96% for at least one reduction by the September meeting. The stronger-than-expected job opening figures could influence these calculations, as robust labor demand typically supports arguments against immediate monetary easing.

The employment picture becomes more complex when considering recent policy developments, including the implementation of new trade measures under the Trump administration. Economists are watching for any signs that tariff policies might be affecting hiring patterns or business confidence across different industries.

Market participants will receive additional labor market insights Thursday when the Bureau of Labor Statistics releases the comprehensive June employment report. Economists are forecasting a continued moderation in hiring activity, with projections calling for 110,000 new nonfarm payroll additions—a notable decline from recent months.

The unemployment rate is expected to tick slightly higher to 4.3%, which would represent a modest increase from the current 4.2% level. If these projections prove accurate, they would reinforce the narrative of a labor market that remains fundamentally healthy but is operating at a more sustainable pace than the breakneck hiring seen in the post-pandemic recovery period.

As one economist noted, while hiring activity remains below historical norms, the combination of low layoff rates and steady job creation suggests the labor market has achieved a state of relative stability rather than deterioration. This balance could prove beneficial for both workers and employers as the economy navigates ongoing policy transitions and global economic uncertainties.

The Strategic Imperative: Why European Healthcare and Life Sciences Companies Should Look To The U.S. Now

In a global economy reshaped by innovation and evolving policy, European Healthcare and Life Sciences companies have a unique opportunity to accelerate growth by investing in the U.S. middle market. Our new thought leadership series—developed by leading M&A professionals from CNM LLP, Cozen O’Connor, NOBLE Capital Markets, and Pathfinder Advisors LLC—dives into the strategic, operational, and financial reasons why the time to act is now.

🔹 Compressed U.S. valuations + innovation-rich sectors
🔹 Favorable budgetary, regulatory, and M&A conditions
🔹 Cross-border synergies driving sustainable global health outcomes

This first installment lays out the business case, key advantages, and regulatory shifts creating ripe conditions for transatlantic healthcare deals. Don’t miss these insights—and get ready for the July 24 webinar that takes the conversation further.

📘 Read the full article

🎙️ Save the Date: July 24 – Expert Webinar

Aurania Resources (AUIAF) – Promising New Data Highlights the Potential for a Significant Copper Discovery


Monday, June 30, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Application of two-dimensional inversion technology. Aurania Resources announced that six highly conductive anomalies have been revealed at the company’s Awacha porphyry copper target based on reprocessed data from a 2021 mobile magnetotellurics (MobileMT) survey using the latest two-dimensional (2D) inversion technology. Compared to the previously employed 1D algorithm, the 2.5D code accounts for the actual topography of the area, resulting in more accurate mapping of subsurface conductivity.

Six promising anomalies at Awacha. New inversion data has confirmed the presence of six high-conductivity anomalies that begin 250 meters from the surface and exhibit deep roots. The anomalies are of significant interest because zones of elevated conductivity often correlate with porphyry copper deposits due to the presence of conductive sulphide minerals and porphyry-related alteration.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Home Depot’s SRS Distribution to Acquire GMS Inc. in $5.5 Billion Deal

GMS Inc. (NYSE: GMS), a major distributor of specialty building products across North America, has entered into a definitive agreement to be acquired by SRS Distribution, a subsidiary of The Home Depot. The transaction, valued at approximately $5.5 billion including net debt, marks a significant step in expanding The Home Depot’s distribution capabilities through its fast-growing specialty trade arm.

Under the agreement, SRS will launch a tender offer to purchase all outstanding shares of GMS for $110.00 per share in cash—representing a 36% premium over GMS’s closing stock price on June 18, 2025. The acquisition is expected to close by the end of The Home Depot’s current fiscal year, pending regulatory approvals and a majority tender of GMS shares.

Founded in 1971, GMS has built a strong presence in the building materials sector, offering a wide range of products including wallboard, ceilings, steel framing, and complementary items through its network of over 320 distribution centers and nearly 100 tool sales and rental locations. The company’s consistent growth has been guided by a strategy focused on expanding its core product sales, growing complementary offerings, extending its platform, and driving productivity and profitability.

Following the acquisition, GMS will continue to operate under its current leadership. CEO John C. Turner Jr. and the existing senior management team will remain at the helm, overseeing day-to-day operations as part of the SRS organization.

The merger aims to significantly enhance service and fulfillment options for both residential and commercial contractors. By combining GMS’s industry leadership and product breadth with SRS’s expansive footprint—already spanning more than 800 locations—the unified business will operate over 1,200 branches and manage a delivery fleet of more than 8,000 trucks.

SRS Distribution CEO Dan Tinker emphasized the value of the partnership, stating that the integration of GMS into the SRS platform will result in a powerful distribution network capable of servicing tens of thousands of job sites daily.

This acquisition also builds on The Home Depot’s strategic use of SRS as a platform for growth. Since acquiring SRS, Home Depot has leveraged synergies including shared service offerings, cross-selling opportunities, and integration of trade credit solutions, contributing to its broader strategy of supporting professional contractors more comprehensively.

Once finalized, the deal is expected to increase The Home Depot’s capacity to serve the growing demands of the pro customer segment, strengthening its position across both residential and commercial construction markets.

AbbVie to Acquire Capstan Therapeutics in $2.1B Deal, Advancing Novel Autoimmune Treatment Technologies

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company pioneering targeted in vivo cell engineering, in a deal valued at up to $2.1 billion. The acquisition includes Capstan’s lead asset, CPTX2309—an investigational therapy targeting B cell-mediated autoimmune diseases—as well as the company’s proprietary targeted lipid nanoparticle (tLNP) platform for RNA delivery.

This strategic move signals AbbVie’s growing commitment to reshaping the treatment landscape for autoimmune diseases. While AbbVie has long been a major player in immunology with blockbuster therapies like Humira and Rinvoq, the addition of Capstan’s in vivo CAR-T capabilities positions the company at the frontier of a new therapeutic modality.

CPTX2309 is an mRNA-based therapy that delivers an anti-CD19 chimeric antigen receptor (CAR) directly into CD8-expressing cytotoxic T cells via Capstan’s tLNP system. Unlike traditional ex vivo CAR-T therapies, which require harvesting and engineering a patient’s cells outside the body before reinfusion, CPTX2309 enables this transformation to happen in vivo. This significantly simplifies the treatment process by eliminating the need for lymphodepletion or complex manufacturing steps—making it potentially more scalable and accessible.

Targeting CD19, a well-validated marker expressed on B cells, CPTX2309 aims to deplete the autoreactive B cells responsible for driving autoimmune diseases such as lupus or multiple sclerosis. The goal is to eliminate the pathogenic immune cells and repopulate the system with naïve, healthy B cells—effectively resetting the immune system and halting disease progression.

AbbVie is not only acquiring a promising clinical candidate but also a platform technology with broad applications. Capstan’s proprietary CellSeeker™ tLNP platform can be adapted to deliver a variety of RNA payloads to specific cell types in vivo, opening possibilities far beyond autoimmune conditions. This could have future implications for oncology, infectious diseases, and more.

As part of the agreement, AbbVie will make a cash payment of up to $2.1 billion at closing, subject to customary regulatory and legal conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act.

This acquisition adds to AbbVie’s expanding immunology pipeline and enhances its positioning in next-generation therapeutic development. By integrating Capstan’s cutting-edge technology, AbbVie aims to develop new approaches that go beyond treating symptoms and instead target the root causes of autoimmune disorders.

The transaction is expected to close later this year. Capstan was advised by Centerview Partners LLC as financial advisor and Cooley LLP as legal counsel. AbbVie did not disclose its legal or advisory team.

This deal reflects a growing industry trend of major pharmaceutical companies investing heavily in advanced RNA delivery platforms and in vivo cell therapies—technologies seen as essential to the next wave of personalized medicine. With this acquisition, AbbVie reaffirms its commitment to driving innovation that transforms the standard of care for patients worldwide.

Take a moment to take a look at more emerging growth biotechnology companies by taking a look at Noble Capital Markets’ analyst Robert LeBoyer’s coverage list.